Catalog No.
RHB08603
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Applications
IHC, WB
Target
Low-density lipoprotein receptor-related protein 4, MEGF7, LRP10, LRP4, LRP-4, KIAA0816, Multiple epidermal growth factor-like domains 7
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
N207/27
Note
For research use only.
Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody., PMID:35614931
LRP4-IgG service line testing in seronegative myasthenia gravis and controls., PMID:35617719
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis., PMID:35835469
LRP4 antibody testing in myasthenia gravis., PMID:35973344
Sorting nexin 17 increases low-density lipoprotein receptor-related protein 4 membrane expression: A novel mechanism of acetylcholine receptor aggregation in myasthenia gravis., PMID:36311763
Development and Application of a Cell-Based Assay for LRP4 Antibody Associated With Myasthenia Gravis., PMID:36606647
Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case-Control study., PMID:36712429
Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis., PMID:36746691
Treatment considerations in myasthenia gravis for the pregnant patient., PMID:36786092
Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?, PMID:36793652
Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis., PMID:36830985
Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events., PMID:36845122
Caution on LRP4 antibody results in patients being evaluated for myasthenia gravis., PMID:36924656
Clinical characteristics of anti-AChR-MuSK-LRP4 antibody-negative myasthenia gravis in China., PMID:36945795
Serological diagnosis of myasthenia gravis and its clinical significance., PMID:37090043
The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts., PMID:37108735
Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions., PMID:37163445
Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients., PMID:37402938
[Pathogenic Autoantibodies in Myasthenia Gravis]., PMID:37431073
Myasthenia gravis and congenital myasthenic syndromes., PMID:37562891
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease., PMID:37564637
Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows., PMID:37759888
Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies., PMID:37865142
Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis., PMID:38203616
Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics., PMID:38316426
Myasthenia gravis-Pathophysiology, diagnosis, and treatment., PMID:38494283
Functional Signature of LRP4 Antibodies in Myasthenia Gravis., PMID:38507656
The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS mice., PMID:38734896
Treating myasthenia gravis beyond the eye clinic., PMID:38789789
Fatigue and associated factors in myasthenia gravis: a nationwide registry study., PMID:38871821
Unusual Presentation of Double-seronegative Myasthenia Gravis with Positive Anti-LRP4 Antibody: Diagnostic Utility of a Videofluoroscopic Swallowing Study., PMID:38897960
Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia., PMID:38949061
Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion., PMID:38967883
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives., PMID:39007037
Myasthenia gravis., PMID:39174248
Agonist antibody to MuSK protects mice from MuSK myasthenia gravis., PMID:39288173
The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments., PMID:39357636
Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review., PMID:39380477
Lipoprotein Receptor-Related Protein 4 Antibody Positivity in the Youngest Patient in the Caucasus Region: A Case Report., PMID:39385918
Heavy duty., PMID:39521071
Surgical treatment of thymic epithelial tumor and myasthenia gravis., PMID:39624461
A clinical perspective on muscle specific kinase antibody positive myasthenia gravis., PMID:39703505
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study., PMID:39862879
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial., PMID:39862880
Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations., PMID:39968461
A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder?, PMID:40062097
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience., PMID:40128464
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects., PMID:40277145
Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review., PMID:40356916
MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis., PMID:40504622
For research use only. Not for human or drug use.
